JP2012508790A - Ｔｒｐｖ３アンタゴニストとしてのクロメノン誘導体 - Google Patents

Ｔｒｐｖ３アンタゴニストとしてのクロメノン誘導体 Download PDF

Info

Publication number
JP2012508790A
JP2012508790A JP2011543830A JP2011543830A JP2012508790A JP 2012508790 A JP2012508790 A JP 2012508790A JP 2011543830 A JP2011543830 A JP 2011543830A JP 2011543830 A JP2011543830 A JP 2011543830A JP 2012508790 A JP2012508790 A JP 2012508790A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
ethenyl
oxo
chromenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011543830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508790A5 (enExample
Inventor
サチン サンダーラル チョードリー，
アブラハム トーマス，
アショク バーウサヘブ カダム，
サチン バサントラオ ドーン，
ブハラット ガンガダール アディク，
ニーリマ カイラトカール−ジョシ，
ビジャ ガナパティ カッティージ，
Original Assignee
グレンマーク ファーマシューティカルズ， エセ．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク ファーマシューティカルズ， エセ．アー． filed Critical グレンマーク ファーマシューティカルズ， エセ．アー．
Publication of JP2012508790A publication Critical patent/JP2012508790A/ja
Publication of JP2012508790A5 publication Critical patent/JP2012508790A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
JP2011543830A 2008-11-17 2009-11-06 Ｔｒｐｖ３アンタゴニストとしてのクロメノン誘導体 Pending JP2012508790A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
IN2420/MUM/2008 2008-11-17
IN2420MU2008 2008-11-17
US13845608P 2008-12-17 2008-12-17
US61/138,456 2008-12-17
IN664MU2009 2009-03-23
IN664/MUM/2009 2009-03-23
US17126509P 2009-04-21 2009-04-21
US61/171,265 2009-04-21
PCT/IB2009/007353 WO2010055384A1 (en) 2008-11-17 2009-11-06 Chromenone derivatives as trpv3 antagonists

Publications (2)

Publication Number Publication Date
JP2012508790A true JP2012508790A (ja) 2012-04-12
JP2012508790A5 JP2012508790A5 (enExample) 2012-12-27

Family

ID=42169675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011543830A Pending JP2012508790A (ja) 2008-11-17 2009-11-06 Ｔｒｐｖ３アンタゴニストとしてのクロメノン誘導体

Country Status (10)

Country Link
US (1) US20110237659A1 (enExample)
EP (1) EP2367810A4 (enExample)
JP (1) JP2012508790A (enExample)
AU (1) AU2009315363A1 (enExample)
CA (1) CA2743276A1 (enExample)
EA (1) EA201190003A1 (enExample)
GE (1) GEP20146025B (enExample)
MX (1) MX2011005147A (enExample)
NZ (1) NZ595779A (enExample)
WO (1) WO2010055384A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160127749A (ko) 2014-03-20 2016-11-04 니폰 조키 세야쿠 가부시키가이샤 쿠마린 유도체를 유효 성분으로서 함유하는 치료·예방제
CN112694392B (zh) * 2020-12-21 2022-11-22 青岛大学 一种trpv3抑制剂及其制备方法
WO2024140431A1 (en) * 2022-12-26 2024-07-04 Iongen Therapeutics Co., Ltd. Compounds comprising heteroaryl rings and compositions and methods thereof
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor
CN121021448B (zh) * 2025-08-26 2026-05-08 江西金丰药业有限公司 一种2-烃基-3-碘色酮类化合物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056124A2 (en) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
JP2008501762A (ja) * 2004-06-08 2008-01-24 ノバルティス アクチエンゲゼルシャフト バニロイドアンタゴニストとして有用なクロモン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033845A (en) * 1975-11-20 1977-07-05 Warner-Lambert Company [2-(4-Oxo-4H-1-benzopyran-2-yl)ethenyl]benzonitriles and benzoic acids
AU508350B2 (en) * 1976-06-16 1980-03-20 Farmitalia Carlo Erba S.P.A. Substicuted 2-vinyl-chromones
US4183945A (en) * 1976-06-16 1980-01-15 Carlo Erba S.P.A. Substituted 2-vinyl-chromones and process for their preparation
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
DE10031809A1 (de) * 2000-07-04 2002-01-17 Basf Ag Neue Flavonoide und ihre Verwendung in kosmetischen und dermatologischen Zubereitungen
US20040009537A1 (en) * 2002-01-11 2004-01-15 Jack Roos Methods of modulating and of identifying agents that modulate intracellular calcium
EP2392328A1 (en) * 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
CA2652307A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501762A (ja) * 2004-06-08 2008-01-24 ノバルティス アクチエンゲゼルシャフト バニロイドアンタゴニストとして有用なクロモン誘導体
WO2007056124A2 (en) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6014007515; ＳＡＮＴＯＳ，Ｃ．Ｍ．　ｅｔ　ａｌ: 'Ａ　ｎｏｖｅｌ　ａｎｄ　ｅｆｆｉｃｉｅｎｔ　ｒｏｕｔｅ　ｆｏｒ　ｔｈｅ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　ｈｙｄｒｏｘｙｌａｔｅｄ　２，３-ｄｉａｒｙｌｘａｎｔｈｏｎｅｓ' Ｓｙｎｌｅｔｔ Ｎｏ．２０, 2007, ｐｐ．３１１３-３１１６ *
JPN6014007516; ＳＡＮＴＯＳ，Ｃ．Ｍ．　ｅｔ　ａｌ: 'Ｎｅｗ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　２，３-ｄｉａｒｙｌｘａｎｔｈｏｎｅｓ' Ｓｙｎｌｅｔｔ Ｎｏ．２０, 2005, ｐｐ．３０９５-３０９８ *
JPN6014007517; ＢＡＫＥＲ，Ｗ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｔｉｃａｌ　ｅｘｐｅｒｉｍｅｎｔｓ　ｉｎ　ｔｈｅ　ｉｓｏｆｌａｖｏｎｅ　ｇｒｏｕｐ．　ＩＶ．　Ｓｙｎｔｈｅｓｉｓ　ｏｆ　２-ｍｅｔｈｙｌｉｒｉｇｅｎｏｌ' Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ Ｖｏｌｕｍｅ　Ｄａｔｅ　１９２８, 1929, ｐｐ．１５２-１６１ *
JPN6014007518; ＢＡＫＥＲ，Ｗ．　ｅｔ　ａｌ: 'Ｉｓｏｆｌａｖｏｎｅ　ｇｒｏｕｐ．　ＩＩ．　Ｓｙｎｔｈｅｓｉｓ　ｏｆ　ｍｅｔｈｙｌｇｅｎｉｓｔｅｉｎ　（ｍｅｔｈｙｌｐｒｕｎｅｔｏｌ）　ｄｉｍｅｔｈｙｌ　ｅｔｈｅｒ　ａｎｄ　ｔｈｅ　ｃｏｎｓｔｉｔｕｔ' Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ , 1926, ｐｐ．２７１３-２７２０ *
JPN6014007519; ＲＥＤＤＹ，Ｃ．Ｒ．　ｅｔ　ａｌ: 'Ａ　ｃｏｎｖｅｎｉｅｎｔ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　２-ｓｔｙｒｙｌｃｈｒｏｍｏｎｅｓ　ｂｙ　ｔｈｅ　ｍｏｄｉｆｉｅｄ　Ｂａｋｅｒ-Ｖｅｎｋａｔａｒａｍａｎ　ｔｒａｎｓｆｏｒｍａｔｉｏｎ' Ｉｎｄｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｅｍｉｓｔｒｙ，　Ｓｅｃｔｉｏｎ　Ｂ：　Ｏｒｇａｎｉｃ　Ｃｈｅｍｉｓｔｒｙ　Ｉｎｃｌｕｄｉｎｇ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２６Ｂ，　Ｎｏ．１０, 1987, ｐｐ．９７４-９７６ *
JPN6014007520; ＧＡＧＧＡＤ，Ｈ．Ｌ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｒｅａｃｔｉｏｎｓ　ｏｆ　１，５-ｄｉｓｕｂｓｔｉｔｕｔｅｄ　４-ｐｅｎｔｅｎｅ-１，３-ｄｉｏｎｅｓ' Ｉｎｄｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｅｍｉｓｔｒｙ，　Ｓｅｃｔｉｏｎ　Ｂ：　Ｏｒｇａｎｉｃ　Ｃｈｅｍｉｓｔｒｙ　Ｉｎｃｌｕｄｉｎｇ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２４Ｂ，　Ｎｏ．１２, 1985, ｐｐ．１２４４-１２４７ *
JPN6014007521; ＭＡＬＩＡＩＡＨ，Ｂ．Ｖ．　ｅｔ　ａｌ: 'Ｆａｃｉｌｅ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　５-ａｒｙｌ-１２Ｈ-ｂｅｎｚｏ［ａ］ｘａｎｔｈｅｎ-１２-ｏｎｅｓ　ｂｙ　ｐｈｏｔｏｏｘｉｄａｔｉｖｅ　ｃｙｃｌｉｚａｔｉｏｎ　ｏｆ　２-ｓｔｙｒｙｌｉｓｏｆ' Ｉｎｄｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｅｍｉｓｔｒｙ，　Ｓｅｃｔｉｏｎ　Ｂ：　Ｏｒｇａｎｉｃ　Ｃｈｅｍｉｓｔｒｙ　Ｉｎｃｌｕｄｉｎｇ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２４Ｂ，　Ｎｏ．８, 1985, ｐｐ．８６２-８６３ *
JPN7014000620; Ｄａｔａｂａｓｅ　ＲＥＧＩＳＴＲＹ *

Also Published As

Publication number Publication date
AU2009315363A1 (en) 2012-01-19
EP2367810A1 (en) 2011-09-28
AU2009315363A2 (en) 2012-04-12
CA2743276A1 (en) 2010-05-20
MX2011005147A (es) 2011-08-29
WO2010055384A1 (en) 2010-05-20
NZ595779A (en) 2013-08-30
EP2367810A4 (en) 2012-06-13
GEP20146025B (en) 2014-01-27
EA201190003A1 (ru) 2012-05-30
US20110237659A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
JP5461525B2 (ja) Ｔｒｐｖ３モジュレーターとしての縮合ピリミジノン化合物
TWI771630B (zh) 溴結構域(bromodomain)抑制劑
US8318928B2 (en) Fused imidazole carboxamides as TRPV3 modulators
AU2016249273A1 (en) Bromodomain inhibitor
JP2012512151A5 (enExample)
JP2012508790A5 (enExample)
US20110237659A1 (en) Chromenone derivatives as trpv3 antagonists
JP2008501762A (ja) バニロイドアンタゴニストとして有用なクロモン誘導体
JP5419894B2 (ja) Ｔｒｐｖ３モジュレーターとしての縮合ピリミジン誘導体
KR20130041456A (ko) Ｔｒｐｖ3 길항제로서 크로메논 유도체
TW201326148A (zh) 做為ｔｒｐｖ３拮抗劑的色烯酮衍生物
CN103159726A (zh) 作为trpv3拮抗剂的色烯酮衍生物
KR20130042671A (ko) Ｔｒｐｖ3 조절제로서 융합된 피리미딘 유도체
CN103172631A (zh) 作为trpv3调节剂的稠合嘧啶衍生物
TW201326168A (zh) 做為trpv3調節劑的稠合嘧啶衍生物
KR20130042189A (ko) Ｔｒｐｖ3 조절제로서의 융합 이미다졸 카르복스아미드

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121106

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20130726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140819